Enanta Pharmaceuticals (ENTA) Non Operating Income (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Non Operating Income of -$1.2 million for Q1 2026, down 313.15% year-on-year from $578000.0 in Q1 2025, and down 86.38% on a QoQ basis from -$661000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Non Operating Income data on file, last reported at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 313.15% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (down 146.91% YoY), and the FY2025 full-year result was $1.8 million, down 53.88% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.2 million, down from -$661000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.9 million in Q2 2023 and bottomed at -$1.2 million in Q1 2026.
- The 5-year median for Non Operating Income is $714000.0 (2022), against an average of $669647.1.
- The widest annual swing landed in 2023, when Non Operating Income surged 620.39%; it then plunged 313.15% in 2026.
- A 5-year view of Non Operating Income shows it stood at $993000.0 in 2022, then slipped by 13.7% to $857000.0 in 2023, then fell by 2.33% to $837000.0 in 2024, then tumbled by 178.97% to -$661000.0 in 2025, then sank by 86.38% to -$1.2 million in 2026.
- The last three Non Operating Income figures came in at -$1.2 million (Q1 2026), -$661000.0 (Q4 2025), and -$282000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -1.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.23 Mn |
| Dec 31, 2025 | -661,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | 667,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 857,000.00 |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 993,000.00 |
| Sep 30, 2022 | 714,000.00 |
| Jun 30, 2022 | 393,000.00 |
| Mar 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 333,000.00 |
| Jun 30, 2021 | 439,000.00 |
| Mar 31, 2021 | 545,000.00 |
| Dec 31, 2020 | 677,000.00 |
| Sep 30, 2020 | 1.15 Mn |
| Jun 30, 2020 | 1.45 Mn |
| Mar 31, 2020 | 1.95 Mn |
| Dec 31, 2019 | 2.08 Mn |
| Sep 30, 2019 | 2.27 Mn |
| Jun 30, 2019 | 2.42 Mn |
| Mar 31, 2019 | 2.25 Mn |
| Dec 31, 2018 | 1.89 Mn |
| Sep 30, 2018 | 1.43 Mn |
| Jun 30, 2018 | 1.34 Mn |
| Mar 31, 2018 | 1.07 Mn |
| Dec 31, 2017 | 960,000.00 |
| Sep 30, 2017 | 660,000.00 |
| Jun 30, 2017 | 600,000.00 |
| Mar 31, 2017 | 549,000.00 |
| Dec 31, 2016 | 524,000.00 |
| Sep 30, 2016 | 471,000.00 |
| Jun 30, 2016 | 447,000.00 |
| Mar 31, 2016 | 472,000.00 |
| Dec 31, 2015 | 329,000.00 |
| Sep 30, 2015 | 509,000.00 |
| Jun 30, 2015 | 287,000.00 |
| Mar 31, 2015 | 210,000.00 |
| Dec 31, 2014 | 301,000.00 |
| Sep 30, 2014 | 236,000.00 |
| Jun 30, 2014 | 36,000.00 |
| Mar 31, 2014 | -76,000.00 |
| Dec 31, 2013 | 87,000.00 |
| Sep 30, 2013 | 258,000.00 |
| Jun 30, 2013 | 40,000.00 |
| Mar 31, 2013 | 252,000.00 |
| Dec 31, 2012 | 48,000.00 |
| Sep 30, 2012 | 44,000.00 |
| Jun 30, 2012 | 27,000.00 |
| Mar 31, 2012 | 16,000.00 |